Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Finlay Minerals Ltd. engages German Mining Networks and renews engagement with Investing News Network
LAURION Retains SMARTIR Marketing Ltd. to Drive Investor Awareness Ahead of Active 2026 Exploration Program
LaFleur Minerals Engages Leading Executive Search Firm to Recruit Senior Mining Executive as Company Advances Toward Gold Production
